COMMENT

Mapping biologically active chemical space to accelerate drug discovery

A specialized platform for innovative research exploration — ASPIRE — in preclinical drug discovery could help study unexplored biologically active chemical space through integrating automated synthetic chemistry, high-throughput biology and artificial intelligence technologies.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Nature Reviews Drug Discovery 18, 83-84 (2019)

References

  1. 1.

    Oprea, T. I. et al. Unexplored therapeutic opportunities in the human genome. Nat. Rev. Drug Discov. 17, 317–332 (2018).

  2. 2.

    Mullard, A. The drugmaker’s guide to the galaxy. Nature 549, 445–447 (2017).

  3. 3.

    Schneider, G. Automating drug discovery. Nat. Rev. Drug Discov. 17, 97–113 (2018).

  4. 4.

    Arrowsmith, C. H. et al. The promise and peril of chemical probes. Nat. Chem. Biol. 11, 536–541 (2015).

  5. 5.

    Lowe, D. AI designs organic syntheses. Nature 555, 592–593 (2018).

Download references

Supplementary Information

  1. 41573_2019_CM16292814_MOESM1_ESM

Competing Interests

The authors declare no competing interests.

Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.

Sign up to Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing